Your browser doesn't support javascript.
loading
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Berns, Katrien; Caumanns, Joseph J; Hijmans, E Marielle; Gennissen, Annemiek M C; Severson, Tesa M; Evers, Bastiaan; Wisman, G Bea A; Jan Meersma, Gert; Lieftink, Cor; Beijersbergen, Roderick L; Itamochi, Hiroaki; van der Zee, Ate G J; de Jong, Steven; Bernards, René.
Afiliación
  • Berns K; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. k.berns@nki.nl.
  • Caumanns JJ; Gynaecologic Oncology, Cancer Research Centre Groningen, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.
  • Hijmans EM; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
  • Gennissen AMC; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
  • Severson TM; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
  • Evers B; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
  • Wisman GBA; Gynaecologic Oncology, Cancer Research Centre Groningen, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.
  • Jan Meersma G; Gynaecologic Oncology, Cancer Research Centre Groningen, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.
  • Lieftink C; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
  • Beijersbergen RL; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
  • Itamochi H; Department of Obstetrics and Gynaecology, Iwate Medical University School of Medicine, Iwate, Morioka, 020-8505, Japan.
  • van der Zee AGJ; Gynaecologic Oncology, Cancer Research Centre Groningen, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.
  • de Jong S; Medical Oncology, Cancer Research Centre Groningen, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands.
  • Bernards R; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. r.bernards@nki.nl.
Oncogene ; 37(33): 4611-4625, 2018 08.
Article en En | MEDLINE | ID: mdl-29760405
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Factores de Transcripción / Proteínas Nucleares / Proteínas / Adenocarcinoma de Células Claras / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Oncogene Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Factores de Transcripción / Proteínas Nucleares / Proteínas / Adenocarcinoma de Células Claras / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Oncogene Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos